Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 10:21 p.m.

    🔍 EVNIN LUKE (Executive)

    Company: Werewolf Therapeutics, Inc. (HOWL)

    Report Date: 2026-01-05

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 71,054

    Detailed Transactions and Holdings:

    • Sold 18,378 shares of Common Stock at $0.64 per share (Direct)
      Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,453,919.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F4
    • Sold 40,761 shares of Common Stock at $0.65 per share (Direct)
      Date: 2026-01-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,413,158.00 | transaction_form_type: 4 | Footnotes: F1, F6, F7, F4
    • Sold 11,915 shares of Common Stock at $0.64 per share (Direct)
      Date: 2026-01-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,401,243.00 | transaction_form_type: 4 | Footnotes: F1, F9, F10, F4

    Footnotes:

    • F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
    • F2: The shares were sold as follows: 1,966 by MPM Asset Management LLC ("AM LLC"), 12,420 by MPM BioVentures 2014, L.P. ("BV 2014"), 828 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 429 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,735 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.63435 to $0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
    • F5: The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF.
    • F6: The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF.
    • F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F8: The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF.
    • F9: The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF.
    • F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6276 to $0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F11: The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF.

Search

News categories